significantnew treatment
Anakinra confirmed superior to DMARDs in systemic AOSD: ANAKINRA-STILLS trial
Adult-Onset Still's Disease →Summary
The randomized ANAKINRA-STILLS trial demonstrated that anakinra as first-line biologic achieves significantly higher complete response rates compared to conventional DMARDs in patients with systemic AOSD. This landmark trial provides level 1 evidence supporting early IL-1 blockade over traditional immunosuppression in systemic-predominant disease.
Related treatments
More from Adult-Onset Still's Disease
landmarkDiagnostic advance
2023 ACR/EULAR classification criteria for Still's disease published
significantMechanism
Gasdermin D and pyroptosis established as central to AOSD cytokine storm
incrementalnew treatment
JAK inhibitors show early promise in refractory AOSD
incrementalMechanism
Neutrophil extracellular traps (NETs) identified in AOSD pathogenesis
ID: adult-onset-stills-disease-update-7Type: new_treatmentImpact: significant